Ekso Bionics Stock Price, News & Analysis

Ekso Bionics Holdings (Nasdaq: EKSO) will announce its financial and business results for Q1 2023 on April 27, 2023. The release will take place after the close of trading, followed by a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results and recent developments. A live webcast will be available on the Company’s website, providing investors with real-time insights. This call presents an opportunity for stakeholders to engage with management regarding the company’s performance in the exoskeleton technology sector, which serves both medical and industrial markets. The replay of the call will also be accessible for one month post-event.

Ekso Bionics (Nasdaq: EKSO) has announced a significant collaboration with SoldierStrong, a non-profit focused on improving Veterans' lives through technology. SoldierStrong will donate an Ekso Indego Therapy device to the Spinal Cord Injury Unit at Augusta's Charlie Norwood VA Medical Center. This donation marks the 30th exoskeleton provided by SoldierStrong over the last decade, reaffirming their commitment to Veterans. The device is designed for individuals with spinal injuries and stroke, enabling them to stand and walk. A donation ceremony is scheduled for April 26, 2023, featuring a demonstration of the device, further emphasizing its clinical benefits. This partnership aims to deliver critical rehabilitation support, enhancing mobility for Veterans.

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) reported its financial results for the year and quarter ending December 31, 2022. For the full year, revenue increased 15% to $12.9 million, driven by a rise in EksoHealth product sales. However, the fourth quarter saw a revenue decline to $3.6 million from $4.1 million in Q4 2021. Gross profit also fell to $1.7 million, reflecting a reduced gross margin of approximately 47%. The net loss for 2022 was $15.1 million, higher than the previous year's loss. As of year-end, the company had $20.5 million in cash, down from $40.4 million a year earlier.

Ekso Bionics (Nasdaq: EKSO) will announce its financial results for Q4 and the full year 2022 on March 28, 2023, after market close. A conference call will take place at 1:30 p.m. PT / 4:30 p.m. ET, where management will discuss financial outcomes and recent business developments. Investors can access the live webcast on the company's website or call in directly. A replay of the webcast will be available for one month afterward. As a pioneer in exoskeleton technology, Ekso Bionics focuses on improving mobility and strength in medical and industrial sectors.

Ekso Bionics (Nasdaq: EKSO) announced its participation in the American Physical Therapy Association’s Combined Sections Meeting, showcasing the new Ekso Indego Therapy integrated with Functional Electrical Stimulation (FES). This innovative therapy aims to enhance rehabilitation for individuals with spinal cord injuries or strokes, offering ten customizable channels for muscle stimulation. The company filed a Premarket Notification 510(k) with the FDA to include this FES technology, marking a significant advancement in patient care. CEO Scott Davis emphasized the commitment to improving patient outcomes through this integration, expected to improve limb function and muscle strength.